Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Kidney failure is an insidious danger but being aware of the early warnings will avoid permanent damage Read ahead to know ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia Ltd (SIX: IDIA) today announced the publication of "A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

There is generally a moment in my office when it all clicks into focus for a patient receiving a new diagnosis of ...

India's sleep crisis: 59 per cent of Indians get less than six hours of uninterrupted rest, raising serious health concerns.

A survey by LocalCircles, a citizen engagement platform, revealed that nearly 59 per cent of Indians get less than six hours of sleep each night. And for many, even that is far from uninterrupted.

Survey by LocalCircles collected over 43,000 responses from 348 districts. Sixty-one percent of the respondents were men ...

March 14 is observed as World Sleep Day, which serves as a reminder of the importance of good sleep. In a recent survey, ...